VivoSeq
Other

Adductor Canal Block

0

Pipeline Programs

6

Active Trials

0

Companies Involved

Adductor Canal Block is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

41

clinical trials

Completed25 · 61%
Unknown status10 · 24%
Not yet recruiting3 · 7%
Recruiting2 · 5%
Active, not recruiting1 · 2%

Trial Activity

41 trials

Adductor Canal Block
Active, not recruiting·OOrthoCarolina Research Institute, Inc.·Phase 2/3·NCT04513145·130 enrolled
Zynrelef Versus Adductor Canal Block
Not yet recruiting·UUniversity of Miami·Phase 4·NCT07216586·120 enrolled
Neostigmine and Dexamethasone in Adductor Canal Block
Completed··N/A·NCT04565301·90 enrolled
Magnesium Sulfate in Adductor Canal Blocks
Completed·QQueen's University·Phase 4·NCT02581683·130 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)